G6PC1 and Obesity: 2,6-DHBA tends to reduce glucose tolerance, at least in short-term treatment [36], does not readily inhibit the mitochondria (our work and [13], [16]), and in our studies, it did not inhibit G6Pase promoter activity, nor did it reduce glucose output from hepatocytes; however, in the context of obesity and long-term drug treatment, beneficial effects of both drugs on inflammation may be exhibited, allowing comparison with pharmacology restricted to SA, such as the uncoupling effect that we have studied.